SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-088247
Filing Date
2024-07-31
Accepted
2024-07-31 08:00:09
Documents
14
Period of Report
2024-07-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20240726.htm   iXBRL 8-K 46899
2 EX-10.1 sabs-ex10_1.htm EX-10.1 164532
3 EX-99.1 sabs-ex99_1.htm EX-99.1 13526
4 GRAPHIC img1871078_0.jpg GRAPHIC 8483
  Complete submission text file 0000950170-24-088247.txt   419969

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20240726.xsd EX-101.SCH 47153
16 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20240726_htm.xml XML 6620
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 241159931
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)